SCRS Welcomes StudyKIK
The Society for Clinical Research Sites (SCRS) announced that StudyKIK has joined the organization as a Global Impact Partner (GIP). SCRS’ GIP Program provides an opportunity for sponsors, CROs, and solution providers to engage with SCRS and its members. Becoming a GIP demonstrates StudyKIK’s commitment to clinical research sites, their desire to develop a deeper understanding of the needs of sites, and contribute to the development and implementation of solutions in the marketplace.
"StudyKIK has believed in SCRS and the vision Christine Pierre founded the organization on, which is to be the unified voice for all research sites, since its inception," said the company's president and co-founder, Matt Miller. "We started StudyKIK with the same vision by building tools to empower sites to succeed in patient recruitment. Becoming an SCRS Global Impact Partner strengthens our commitment to supporting research sites and connecting patients to clinical trials."
“By joining SCRS as a GIP, StudyKIK has demonstrated their commitment to a strong and unified site community,” said SCRS president Casey Orvin. “StudyKIK has had a consistent presence at SCRS’ Site Solutions Summits throughout the years, and we are looking forward to expanding our engagement with the company through the GIP program.”
For more information, visit www.MySCRS.org
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
